CAS 739-71-9|trimipramine
Introduction：Basic information about CAS 739-71-9|trimipramine, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | trimipramine | ||
|---|---|---|---|
| CAS Number | 739-71-9 | Molecular Weight | 294.43400 |
| Density | 0.9912 (rough estimate) | Boiling Point | 426.2°C (rough estimate) |
| Molecular Formula | C20H26N2 | Melting Point | 45° |
| MSDS | / | Flash Point | 9℃ |
| Symbol | GHS02, GHS06, GHS08 | Signal Word | Danger |
Names
| Name | trimipramine |
|---|---|
| Synonym | More Synonyms |
trimipramine BiologicalActivity
| Description | Trimipramine is a 5-HT receptor antagonist, with pKi binding values of 6.39, 8.10, 4.66 for 5-HT1C, 5-HT2 and 5-HT1A, respectively. Trimipramine is also a potent and selective inhibitor targeting human noradrenaline (hNAT), serotonin (hSERT) and organic cation transporters (hOCT1, hOCT2) with IC50 values of 4.99 μM, 2.11 μM, 3.72 μM, 8.00 μM, respectively. Trimipramine has vascular activity and anxiolytic efficacy[1][2][3]. |
|---|---|
| Related Catalog | Research Areas >>Neurological DiseaseSignaling Pathways >>GPCR/G Protein >>5-HT ReceptorSignaling Pathways >>Neuronal Signaling >>5-HT ReceptorSignaling Pathways >>Anti-infection >>Bacterial |
| Target | 5-HT1C Receptor:6.39 (pKi) 5-HT2 Receptor:8.10 (pKi) 5-HT1A Receptor:4.66 (pKi) |
| In Vitro | Trimipramine displays much higher affinity for 5-HT2 than for 5-HT1C receptors[1]. Trimipramine is a moderate inhibitor of the human NAT and SERT, with the IC50 values of 4.99 μM and 2.11 μM, respectively[2]. SERT and NAT could represent a target for the antidepressant effects of trimipramine (1 mM, 0.1 mM, 0.01 mM, 1 μM, 0.1 μM; 10 min; HEK293 cells)[2]. |
| In Vivo | Trimipramine (5 mg/kg/d; 14 d; chronic administration) acts as functions in rats:1. Increasing concentration of regional 5-HT. 5-HT is highest in the frontal cortex and the hippocampus, followed by the olfactory tubercles and the hypothalamus. 2. Decreasing the number of frontal cortex 5-HT2 and striatal DA D2 receptors. 3. Increasing in the brain regional level of monoamines and metabolites. thus indicates a greater synthesis rate for dopamine (DA) and 5-HT coinciding with an adaptive down regulation of 5-HT2 and DA D2 receptors[3]. Animal Model: Male Wistar rats (220-250 g); implanted osmotic minipump subcutaneously in the dorsal thoracic interscapular region[3] Dosage: 5 mg/kg/day Administration: Delivered by smotic minipump; 14 days Result: Decreased the number of frontal cortex 5-HT2 and striatal DA D2 receptors, thus blocked the uptake of 5-HT and dopamine (DA). |
| References | [1]. Jenck F, et al. Evidence for a role of 5-HT1C receptors in the antiserotonergic properties of some antidepressant drugs. Eur J Pharmacol. 1993 Feb 9. 231(2):223-9. [2]. Haenisch B, et al. Inhibitory potencies of trimipramine and its main metabolites at human monoamine and organic cation transporters. Psychopharmacology (Berl). 2011 Sep. 217(2):289-95. [3]. Juorio AV, et al. The effects of chronic trimipramine treatment on biogenic amine metabolism and on dopamine D2, 5-HT2 and tryptamine binding sites in rat brain. Gen Pharmacol. 1990. 21(5):759-62. |
Chemical & Physical Properties
| Density | 0.9912 (rough estimate) |
|---|---|
| Boiling Point | 426.2°C (rough estimate) |
| Melting Point | 45° |
| Molecular Formula | C20H26N2 |
| Molecular Weight | 294.43400 |
| Flash Point | 9℃ |
| Exact Mass | 294.21000 |
| PSA | 6.48000 |
| LogP | 4.18600 |
| Index of Refraction | 1.6450 (estimate) |
| Storage condition | 2-8°C |
Toxicological Information
CHEMICAL IDENTIFICATION |
ACUTE TOXICITY DATA - TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human
- DOSE/DURATION :
- 18 mg/kg
- TOXIC EFFECTS :
- Cardiac - other changes
- REFERENCE :
- PSDTAP Proceedings of the European Society for the Study of Drug Toxicity. (Princeton, NJ 08540) V.1-15, 1963-74. For publisher information, see PESTD5. Volume(issue)/page/year: 6,171,1965
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 250 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- BCFAAI Bollettino Chimico Farmaceutico. (Societa Editoriale Farmaceutica, Via Ausonio 12, 20123 Milan, Italy) V.33- 1894- Volume(issue)/page/year: 102,753,1963
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 145 mg/kg
- TOXIC EFFECTS :
- Behavioral - somnolence (general depressed activity) Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - other changes
- REFERENCE :
- CRSBAW Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales. (SPPIF, B.P.22, F-41353 Vineuil, France) V.1- 1849- Volume(issue)/page/year: 155,307,1961
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 200 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- BCFAAI Bollettino Chimico Farmaceutico. (Societa Editoriale Farmaceutica, Via Ausonio 12, 20123 Milan, Italy) V.33- 1894- Volume(issue)/page/year: 102,753,1963
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 42 mg/kg
- TOXIC EFFECTS :
- Behavioral - somnolence (general depressed activity) Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - other changes
- REFERENCE :
- CRSBAW Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales. (SPPIF, B.P.22, F-41353 Vineuil, France) V.1- 1849- Volume(issue)/page/year: 155,307,1961
Safety Information
| Symbol | GHS02, GHS06, GHS08 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H225-H301 + H311 + H331-H370 |
| Precautionary Statements | P210-P260-P280-P301 + P310-P311 |
| Hazard Codes | F,T |
| Risk Phrases | 11-23/24/25-39/23/24/25 |
| Safety Phrases | 16-36/37-45 |
| RIDADR | UN 3249 |
| Packaging Group | III |
| Hazard Class | 6.1(b) |
Articles27
More Articles| Evaluation of the matrix effect of different sample matrices for 33 pharmaceuticals by post-column infusion. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 1000 , 84-94, (2015) Matrix effects that occur during quantitative measurement by liquid chromatography mass spectrometry specifically when using electrospray ionization are a widely recognized phenomenon. Sample matrix c... | |
| Antidepressants for patients with tinnitus. Cochrane Database Syst. Rev. 9 , CD003853, (2012) This is an update of a Cochrane review first published in The Cochrane Library in Issue 4, 2006 and previously updated in 2009.Tinnitus is described as the perception of sound or noise in the absence ... | |
| Seizures after single-agent overdose with pharmaceutical drugs: analysis of cases reported to a poison center. Clin. Toxicol. (Phila.) 52(6) , 629-34, (2014) Seizures during intoxications with pharmaceuticals are a well-known complication. However, only a few studies report on drugs commonly involved and calculate the seizure potential of these drugs.To id... |
Synonyms
| (+-)-1-cyclohexyl-1-phenyl-3-piperidino-propan-1-ol,hydrochloride |
| (+-)-1-Cyclohexyl-1-phenyl-3-piperidino-propan-1-ol,Hydrochlorid |
| tremin |
| (+/-)-Trihexyphenidyl hydrochloride |
| EINECS 212-008-3 |
| Trihexy |
| 5-(3-dimethylamino-2-methylpropyl)-10,11-dihydro-5H-dibenz (b,f) azepine acid maleate |
| triiodothyronine |
| Trimipramine |
| paralest |
| 8-Chloro-3-methoxy-11-(1-methyl-4-piperidinyl)-6,11-dihydro-5H-benzo[5,6]-cyclohepta[1,2-b]pyridin-11-ol |
| [3-(10,11-dihydro-dibenzo[b,f]azepin-5-yl)-2-methyl-propyl]-dimethyl-amine |
| 10,11-dihydro-5-(3-dimethylamino-2-methylpropyl)-5H-dibenz(b,f)azepine |
| peragit |
| Sedrina |
| timipramine |
| cyclodol |
| trihexylphenidyl HCl |
| pacitane |
| Broflex |
| 3,3',5-triiodothyronine |
| L-3,3',5-triiodothyronine |
| 3,5,3'-triiodothyronine |
| pipanol |
